A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency

Barbara K. Burton(Women & Children's Hospital of Buffalo), Anthony Quinn(Synageva BioPharma (United States)), Gregory M. Enns(Lucile Packard Children's Hospital), Fatih Süheyl Ezgü(Gazi University), Maurizio Scarpa(University of Udine), Zachary Goodman(Inova Health System), Christina M. Laukaitis(University of Arizona), Can Fıçıcıoğlu(Children's Hospital of Philadelphia), Manisha Balwani(Icahn School of Medicine at Mount Sinai), Yijun Yang(Synageva BioPharma (United States)), Heidi Peters(Royal Children's Hospital), Edward Neilan(Boston Children's Hospital), Sandra Rojas-Caro(Synageva BioPharma (United States)), Vassili Valayannopoulos(Regeneron (United States)), Ivo Barić(University Hospital Centre Zagreb), Eugen Mengel(University of Hohenheim), John P. Kane(University of California, San Francisco), Katryn N. Furuya(Alfred I. duPont Hospital for Children), Alejandra Consuelo‐Sánchez(Hospital Infantil de México Federico Gómez), S. L. Nightingale(John Hunter Children's Hospital), Vratislav Smolka(Palacký University Olomouc), Stephen Eckert(Synageva BioPharma (United States)), François Feillet(Hôpital d'Enfants), C. Camarena Grande(Hospital Universitario La Paz), Karl Otfried Schwab(University Medical Center Freiburg), Marnie J. Wood(Royal Brisbane and Women's Hospital), Richard W. Erbe(Women & Children's Hospital of Buffalo), Mahmut Çöker(Ege University), T. Burrow(Cincinnati Children's Hospital Medical Center), Patrick Deegan(Addenbrooke's Hospital)
New England Journal of Medicine
September 10, 2015
Cited by 244


Related Papers